Full history for every metric is available with a Kvantra account
Kineta, Inc. (KA)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 5 | 10 | 9 | 2 | 5 | 0 | 4 |
| Operating profit | $m | -14 | -7 | |||||
| Net profit | $m | -59 | -14 | -12 | -63 | -14 | -17 | -8 |
| EPS reported | $ | -1.42 | -0.66 | |||||
| Operating cashflow per share | $ | -0.96 | -0.96 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.96 | -0.96 | |||||
| Free cash flow | $m | -12 | -4 | |||||
| Net debt | $m | -0 | 0 | |||||
| Book value equity | $m | -12 | -13 | |||||
| Book value per share | $ | -0.99 | -1.02 | |||||
| Number of shares | m | 12.1 | 12.9 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -0.62 | -0.53 | |||||
| P/S LTM | x | 0.00 | 1.62 | |||||
| P/FCF LTM | x | -0.65 | -1.79 | |||||
| EV/EBITDA LTM | x | -0.55 | -0.87 | |||||
| EV/Sales LTM | x | 0.00 | 1.70 | |||||
| Earnings Yield LTM | % | -229.48% | -246.41% | |||||
| FCF Yield | % | -154.94% | -55.98% | |||||
| Quality | ||||||||
| ROE | % | 142.40% | 374.84% | |||||
| ROIC | % | 120.41% | 120.41% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -100.00% | +427.10% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -18.39 | -6.27 | |||||
| Net Debt/EBITDA | x | 0.00 | 0.00 | |||||
| EBIT/Net interest | x | -98.06 | -98.06 | |||||
| Net debt/market cap | % | -0.07% | 4.61% | |||||
| Net debt/Equity | x | 0.00 | -0.02 | |||||
| Gross debt/equity | x | -0.05 | -0.05 | |||||
Company overview
Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing immunotherapies, with a focus on oncology, neuroscience, and biodefense applications. The company engages in partnerships with a variety of entities, including private companies, government bodies, and other industry stakeholders. Among its significant strategic collaborators are Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Established in 2007, Kineta, Inc. was previously known as Lecura, Inc. and has its base of operations in Seattle, Washington.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kineta, Inc. (KA)
Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing immunotherapies, with a focus on oncology, neuroscience, and biodefense applications. The company engages in partnerships with a variety of entities, including private companies, government bodies, and other industry stakeholders. Among its significant strategic collaborators are Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Established in 2007, Kineta, Inc. was previously known as Lecura, Inc. and has its base of operations in Seattle, Washington.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free